Impax Asset Management Group plc Has $396.09 Million Stake in Agilent Technologies, Inc. (NYSE:A)

Impax Asset Management Group plc lifted its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 8.2% during the 3rd quarter, Holdings Channel reports. The firm owned 2,667,616 shares of the medical research company’s stock after purchasing an additional 203,234 shares during the period. Agilent Technologies makes up 1.6% of Impax Asset Management Group plc’s holdings, making the stock its 19th largest holding. Impax Asset Management Group plc’s holdings in Agilent Technologies were worth $396,088,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Crewe Advisors LLC raised its stake in Agilent Technologies by 114.8% in the second quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 101 shares in the last quarter. Livelsberger Financial Advisory bought a new position in Agilent Technologies in the 3rd quarter valued at about $28,000. Ridgewood Investments LLC bought a new position in Agilent Technologies in the 2nd quarter valued at about $29,000. Fortitude Family Office LLC raised its position in shares of Agilent Technologies by 68.3% in the 3rd quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company’s stock valued at $35,000 after buying an additional 95 shares in the last quarter. Finally, Ashton Thomas Private Wealth LLC bought a new stake in shares of Agilent Technologies during the 2nd quarter worth approximately $39,000.

Agilent Technologies Trading Up 1.4 %

Shares of NYSE:A traded up $1.94 during midday trading on Monday, reaching $138.81. The company’s stock had a trading volume of 495,763 shares, compared to its average volume of 1,676,897. Agilent Technologies, Inc. has a fifty-two week low of $104.09 and a fifty-two week high of $155.35. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.37 and a current ratio of 1.78. The firm has a 50 day moving average price of $139.73 and a two-hundred day moving average price of $138.08. The firm has a market capitalization of $39.88 billion, a price-to-earnings ratio of 28.40, a PEG ratio of 6.26 and a beta of 1.07.

Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.06. The firm had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.56 billion. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. The company’s revenue for the quarter was down 5.6% compared to the same quarter last year. During the same period in the prior year, the business earned $1.43 EPS. As a group, analysts forecast that Agilent Technologies, Inc. will post 5.24 earnings per share for the current year.

Agilent Technologies Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 23rd. Shareholders of record on Tuesday, October 1st were paid a $0.236 dividend. This represents a $0.94 annualized dividend and a yield of 0.68%. The ex-dividend date was Tuesday, October 1st. Agilent Technologies’s dividend payout ratio (DPR) is currently 19.50%.

Insider Activity

In other news, CEO Padraig Mcdonnell sold 1,958 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total transaction of $283,910.00. Following the transaction, the chief executive officer now directly owns 24,118 shares of the company’s stock, valued at $3,497,110. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, SVP Dominique Grau sold 9,990 shares of the stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $145.00, for a total value of $1,448,550.00. Following the completion of the sale, the senior vice president now directly owns 40,011 shares of the company’s stock, valued at approximately $5,801,595. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Padraig Mcdonnell sold 1,958 shares of Agilent Technologies stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total transaction of $283,910.00. Following the transaction, the chief executive officer now directly owns 24,118 shares in the company, valued at $3,497,110. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 11,995 shares of company stock worth $1,739,510.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on A. Bank of America lifted their price target on Agilent Technologies from $140.00 to $147.00 and gave the company a “neutral” rating in a research note on Thursday, August 22nd. Barclays lifted their target price on Agilent Technologies from $135.00 to $145.00 and gave the company an “underweight” rating in a research report on Tuesday, October 15th. Wells Fargo & Company began coverage on shares of Agilent Technologies in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $157.00 price target on the stock. UBS Group lifted their price target on shares of Agilent Technologies from $141.00 to $150.00 and gave the company a “neutral” rating in a report on Thursday, August 22nd. Finally, TD Cowen increased their price objective on shares of Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $144.36.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.